Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | BCR | P11274 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anisole SCHEMBL9798277 | 0.87 | CA4 (0.70) | CA4ALDH1A1TDP1L3MBTL1LTA4H | |
| Anisole SCHEMBL5188448 | 0.87 | CA4 (0.70) | CA4ALDH1A1TDP1L3MBTL1LTA4H | |
| SCHEMBL9152375 | 0.87 | CA4 (0.68) | CA4NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL291776 | 0.87 | CA4 (0.68) | CA4NPC1RAB9AKDM4EALDH1A1 | |
| Biphenyl SCHEMBL11784329 | 0.87 | CA4 (0.68) | CA4NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL17283658 | 0.87 | CA4 (0.68) | CA4NPC1RAB9AKDM4EALDH1A1 | |
| Anisole SCHEMBL10685829 | 0.85 | CA4 (0.67) | CA4ALDH1A1TDP1L3MBTL1LTA4H | |
| Water SCHEMBL3540832 | 0.84 | CA4 (0.65) | CA4NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL28478235 | 0.84 | CA4 (0.65) | CA4NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL29220727 | 0.84 | CA4 (0.65) | CA4NPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858619-B2 | Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
| US-6849732-B2 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1095936-B1 | Intermediates useful for the preparation of metallproteinase inhibitors | AGOURON PHARMA (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030130506-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2003-07-10 | — | — | US | disclosed |
| US-6500948-B1 | SUCH AS N-HYDROXY-4-(4-((PYRID-4-YL)OXY)BENZENESULFONYL)-2,2-DIMETHYL-TETRAHYDRO-2H -1,4-THIAZINE-3-CARBOXYLIC ACID | AGOURON PHARMACEUTICALS, INC. | 2002-12-31 | — | — | US | disclosed |
| EP-1095936-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6153757-A | A PRODRUG, SALT OR SOLVATE AS ANTITUMOR AGENT AND ENZYME INHIBITOR FOR INHIBITING METALLOPROTEINASES, TUMOR NECROSIS FACTOR | AGOURON PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0874830-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997020824-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-12 | — | — | WO | disclosed |
| EP-0088585-B1 | 3-BENZOYL-2-MERCAPTOPROPIONIC ACID DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1985-01-23 | — | — | EP | disclosed |
| US-4472316-A | ANTILIPEMIC AGNETS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1984-09-18 | — | — | US | disclosed |
| EP-0088585-A1 | 3-Benzoyl-2-mercaptopropionic acid derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1983-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130506-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | MMP9, MMP3, MMP2 | CA4 107/4885NPC1 1033/4885RAB9A 1992/4885 |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | MMP9, MMP3, MMP2 | CA4 804/4885NPC1 674/4885RAB9A 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.